Revisiting the role of durable polymers in cardiovascular devices

References

• Nakazawa G, Finn AV, Vorpahl M, et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57:390–398.
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701–705.
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141–149.
   PubMed Web of Science ®Google Scholar
• Weisz G, Leon MB, Holmes DR, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent In De-Novo Native Coronary Lesions) trial. J Am Coll Cardiol. 2009;53:1488–1497.
   PubMed Web of Science ®Google Scholar
• Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2009;2:1248–1259.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8. DOI:10.1161/CIRCINTERVENTIONS.114.002230.
   Web of Science ®Google Scholar
• Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211–223.
   PubMed Web of Science ®Google Scholar
• Natsuaki M, Morimoto T, Furukawa Y, et al. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 Years) follow-up of the coronary revascularization demonstrating outcome study-kyoto registry cohort-2. Circ Cardiovasc Interv. 2014;7:168–179.
   PubMed Web of Science ®Google Scholar
• Habib A, Karmali V, Polavarapu R, et al. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via s6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol. 2013;61:971–980.
   PubMed Web of Science ®Google Scholar
• A V F, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500–1510.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–1193.
   PubMed Web of Science ®Google Scholar
• Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13:183–188.
   PubMed Web of Science ®Google Scholar
• Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379–2384.
   PubMed Web of Science ®Google Scholar
• Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270–278.
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–2441.
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.
   PubMed Web of Science ®Google Scholar
• Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. Bare Metal Stents Coronary Artery Disease: Meta-Analysis Eur Heart J. 2006;27:2784–2814.
   Google Scholar
• Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019.
   PubMed Web of Science ®Google Scholar
• Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997.
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (London, England). 2007;370:937–948.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039.
   PubMed Web of Science ®Google Scholar
• Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008.
   PubMed Web of Science ®Google Scholar
• Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-cypher registry. Circulation. 2006;113:1434–1441.
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678.
   PubMed Web of Science ®Google Scholar
• Epstein AJ, Polsky D, Yang F, et al. Coronary revascularization trends in the United States, 2001-2008. Jama. 2011;305:1769–1776.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138–1145.
   PubMed Web of Science ®Google Scholar
• Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653–662.
   PubMed Web of Science ®Google Scholar
• Yamaji K, Räber L, Zanchin T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37:3386–3395.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Van Mieghem CAG, Ong ATL, et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the rapamycin-eluting and taxus stent evaluated at Rotterdam cardiology hospital registries (RESEARCH and T-SEARCH). Circulation. 2005;111:1383–1389.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
   PubMed Web of Science ®Google Scholar
• Galløe AM, Kelbæk H, Thuesen L, et al. 10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents. J Am Coll Cardiol. 2017;69:616–624.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–1322.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147–2159.
   PubMed Web of Science ®Google Scholar
• Kang S-J, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation. 2011;123:2954–2963.
   PubMed Web of Science ®Google Scholar
• Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016;133:650–660.
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–342.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Biondi-Zoccai G, Della RD, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393–1402.
   PubMed Web of Science ®Google Scholar
• Xu B, Yang Y, Yuan Z, et al. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China. JACC Cardiovasc Interv. 2013;6:664–670.
   PubMed Web of Science ®Google Scholar
• Sunny MC, Sharma CP. Titanium-protein interaction: changes with oxide layer thickness. J Biomater Appl. 1991;6:89–98.
   PubMedGoogle Scholar
• Courtney JM, Lamba NM, Sundaram S, et al. Biomaterials for blood-contacting applications. Biomaterials. 1994;15:737–744.
   PubMed Web of Science ®Google Scholar
• Sheppard JI, McClung WG, Feuerstein IA. Adherent platelet morphology on adsorbed fibrinogen: effects of protein incubation time and albumin addition. J Biomed Mater Res. 1994;28:1175–1186.
   PubMed Web of Science ®Google Scholar
• Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25:5681–5703.
   PubMed Web of Science ®Google Scholar
• Garfinkle AM, Hoffman AS, Ratner BD, et al. Effects of a tetrafluoroethylene glow discharge on patency of small diameter dacron vascular grafts. Trans Am Soc Artif Intern Organs. 1984;30:432–439.
   PubMedGoogle Scholar
• Lin JC, Tiong SL, Chen CY. Surface characterization and platelet adhesion studies on fluorocarbons prepared by plasma-induced graft polymerization. J Biomater Sci Polym Ed. 2000;11:701–714.
   PubMed Web of Science ®Google Scholar
• Massa TM, McClung WG, Yang ML, et al. Fibrinogen adsorption and platelet lysis characterization of fluorinated surface-modified polyetherurethanes. J Biomed Mater Res A. 2007;81:178–185.
   PubMed Web of Science ®Google Scholar
• Hasebe T, Yohena S, Kamijo A, et al. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. J Biomed Mater Res A. 2007;83:1192–1199.
   PubMed Web of Science ®Google Scholar
• Uniyal S, Brash JL. Patterns of adsorption of proteins from human plasma onto foreign surfaces. Thromb Haemost. 1982;47:285–290.
   PubMed Web of Science ®Google Scholar
• Vroman L. Problems in the development of materials that are compatible with blood. Biomater Med Devices Artif Organs. 1984-1985;12:307–323.
   PubMed Web of Science ®Google Scholar
• Nojiri C, Okano T, Koyanagi H, et al. In vivo protein adsorption on polymers: visualization of adsorbed proteins on vascular implants in dogs. J Biomater Sci Polym Ed. 1992;4:75–88.
   PubMed Web of Science ®Google Scholar
• Grunkemeier JM, Tsai WB, McFarland CD, et al. The effect of adsorbed fibrinogen, fibronectin, von Willebrand factor and vitronectin on the procoagulant state of adherent platelets. Biomaterials. 2000;21:2243–2252.
   PubMed Web of Science ®Google Scholar
• Tsai K-C, Chen J-S, Huang J-H, et al. Staphylococcal infection-related constrictive pericarditis with formation of a mycotic aneurysm in the right coronary artery. J Formos Med Assoc. 2015;114:1149–1150.
   PubMed Web of Science ®Google Scholar
• Chiumiento A, Lamponi S, Barbucci R. Role of fibrinogen conformation in platelet activation. Biomacromolecules. 2007;8:523–531.
   PubMed Web of Science ®Google Scholar
• Lyman DJ, Metcalf LC, Albo D, et al. The effect of chemical structure and surface properties of synthetic polymers on the coagulation of blood. III. In vivo adsorption of proteins on polymer surfaces. Trans Am Soc Artif Intern Organs. 1974;20:474–478.
   PubMedGoogle Scholar
• Szott LM, Irvin CA, Trollsas M, et al. Blood compatibility assessment of polymers used in drug eluting stent coatings. Biointerphases. 2016;11:29806.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Cheng Q, Yahagi K, et al. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc Interv. 2015;8:1248–1260.
   PubMed Web of Science ®Google Scholar
• Sawyer PN, Srinivasan S. The role of electrochemical surface properties in thrombosis at vascular interfaces: cumulative experience of studies in animals and man. Bull N Y Acad Med. 1972;48:235–256.
   PubMedGoogle Scholar
• Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400–1409.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drug-eluting and bare-metal stents. J Am Coll Cardiol. 2015;65:2496–2507.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. Bmj. 2013;347:f6625.
   PubMed Web of Science ®Google Scholar
• Habib A, Karmali V, Polavarapu R, et al. Sirolimus-FKBP12.6 Impairs Endothelial Barrier function through protein kinase c- activation and disruption of the p120-Vascular endothelial cadherin interaction. Arterioscler Thromb Vasc Biol. 2013;33:2425–2431.
   PubMed Web of Science ®Google Scholar
• Dejana E, Orsenigo F. Endothelial adherens junctions at a glance. J Cell Sci. 2013;126:2545–2549.
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Huibregtse BA, Pennington DE, et al. Comparison of the SYNERGY with the PROMUS (XIENCE V) and bare metal and polymer-only Element control stents in porcine coronary arteries. EuroIntervention. 2012;8:250–257.
   PubMed Web of Science ®Google Scholar
• Von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet (London, England). 2016;388:2607–2617.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Meredith IT, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial. Circ Cardiovasc Interv. 2015;8. DOI:10.1161/CIRCINTERVENTIONS.114.002372.
   Web of Science ®Google Scholar
• Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Arte. Eur Heart J. 2015;35:2021–2031.
   Web of Science ®Google Scholar
• Meredith IT, Verheye S, Weissman NJ, et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2013;9:308–315.
   PubMed Web of Science ®Google Scholar
• Mischie AN, Nazzaro MS, Fiorilli R, et al. Head-to-head comparison of sirolimus-eluting stent versus bare metal stent evaluation of the coronary endothelial dysfunction in the same patient presenting with multiple coronary artery lesions: the CREDENTIAL study. Catheter Cardiovasc Interv. 2013;82:E184–E191.
   PubMed Web of Science ®Google Scholar
• Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561–566.
   PubMed Web of Science ®Google Scholar
• Kimura T, Abe K, Shizuta S, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002;105:2986–2991.
   PubMed Web of Science ®Google Scholar
• Inoue K, Abe K, Ando K, et al. Pathological analyses of long-term intracoronary Palmaz–Schatz stenting. Cardiovasc Pathol. 2004;13:109–115.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Menné T. Metal allergy–a review on exposures, penetration, genetics, prevalence, and clinical implications. Chem Res Toxicol. 2010;23:309–318.
   PubMed Web of Science ®Google Scholar
• Halwani DO, Anderson PG, Lemons JE, et al. In-vivo corrosion and local release of metallic ions from vascular stents into surrounding tissue. J Invasive Cardiol. 2010;22:528–535.
   PubMed Web of Science ®Google Scholar